The janus face of cyclophosphamide: A sterile inflammatory response that potentiates cancer immunotherapy

OncoImmunology

Volumn 2, Issue 9, 2013, Pages

  Ziccheddu, Giovanna ^a   Proietti, Enrico ^a   Moschella, Federica ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Alkylating agents; Cellular response to anticancer drugs; Chemoimmunotherapy; Gene expression profiling; Immunomodulation; Immunotherapy; Sterile inflammation; Type I interferon

Indexed keywords

CYCLOPHOSPHAMIDE; INTERFERON; PROTEIN P53;

ANTIGEN PRESENTING CELL; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CYTOKINE RELEASE; DENDRITIC CELL; DRUG MEGADOSE; GENE EXPRESSION; GENE ONTOLOGY; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOMODULATION; INFLAMMATION; INNATE IMMUNITY; LYMPHOCYTE; LYMPHOCYTE DEPLETION; MONOCYTE; NONHUMAN;

EID: 84890283544     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.25789     Document Type: Article

References (10)

1. Proietti E, Moschella F, Capone I, Belardelli F. Exploitation of the propulsive force of chemotherapy for improving the response to cancer immunotherapy. Mol Oncol 2012; 6:1-14; PMID:22177803; http:// dx.doi.org/10.1016/j.molonc.2011.11.005
2. Bracci L, Moschella F, Sestili P, La Sorsa V, Valentini M, Canini I, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res 2007; 13:644-53; PMID:17255288; http://dx.doi.org/10.1158/1078- 0432.CCR-06-1209
3. Schiavoni G, Mattei F, Di Pucchio T, Santini SM, Bracci L, Belardelli F, et al. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 2000; 95:2024-30; PMID:10706870
4. Salem ML, Díaz-Montero CM, Al-Khami AA, El-Naggar SA, Naga O, Montero AJ, et al. Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C). J Immunol 2009; 182:2030-40; PMID:19201856; http://dx.doi.org/10.4049/jimmunol. 0801829
5. Moschella F, Valentini M, Aricò E, Macchia I, Sestili P, D'Urso MT, et al. Unraveling cancer chemoimmunotherapy mechanisms by gene and protein expression profiling of responses to cyclophosphamide. Cancer Res 2011; 71:3528-39; PMID:21444678; http:// dx.doi.org/10.1158/0008-5472.CAN-10-4523
6. Moschella F, Torelli GF, Valentini M, Urbani F, Buccione C, Petrucci MT, et al. Cyclophosphamide induces a type I interferon-associated sterile inflammatory response signature in cancer patients' blood cells: implications for cancer chemoimmunotherapy. Clin Cancer Res 2013; PMID:23759676; http://dx.doi. org/10.1158/1078-0432.CCR-12-3666
7. Aricò E, Belardelli F. Interferon-a as antiviral and antitumor vaccine adjuvants: mechanisms of action and response signature. J Interferon Cytokine Res 2012; 32:235-47; PMID:22490303; http://dx.doi. org/10.1089/jir.2011.0077
8. Muñoz-Fontela C, Macip S, Martínez-Sobrido L, Brown L, Ashour J, García-Sastre A, et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J Exp Med 2008; 205:1929-38; PMID:18663127; http://dx.doi.org/10.1084/jem.20080383
9. Berda-Haddad Y, Robert S, Salers P, Zekraoui L, Farnarier C, Dinarello CA, et al. Sterile inflammation of endothelial cell-derived apoptotic bodies is mediated by interleukin-1a. Proc Natl Acad Sci U S A 2011; 108:20684-9; PMID:22143786; http://dx.doi. org/10.1073/pnas.1116848108
10. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. J Leukoc Biol 2007; 81:584-92; PMID:17135573; http://dx.doi.org/10.1189/jlb.0806510